Developing Next Generation Agents for Psychedelic Therapy
Lophora is a clinical-stage biotech company developing novel, next generation psychedelic agents to treat a multitude of psychiatric disorders
About us
Founded in 2018 Lophora has successfully finished initial characterization of its lead candidate LPH-5 through initial funding granted by the BioInovation Institute (Novo Nordisk Foundation) and will initiate first-in-human trials by 2024.
The company has identified and patented a new class of proprietary ligands that share a pharmacological profile with psilocybin, which has shown promising clinical results in the treatment of depression.
Lophora holds a unique position in the market for Psychedelic Therapy therapies of the future.
Given our unique technology and knowledge of the field, we are confident that we are moving ahead of a global market shift towards Psychedelic Therapy as a treatment for various CNS disorders.
Lophora Founders Team at BioInnovation Institute (October 2020)
News
Lophora Closes Bridge Round to Strengthen Global Patent Portfolio and prepare for Phase I
- August 24, 2023
Lophora completes preclinical development of LPH-5 for treatment-resistant depression
- November 22, 2022
Lophora Receives Additional Funding to Complete Pre-Clinical Development of LPH-5 – A Novel and Innovative Agent to Address Treatment-Resistant Depression
- March 2, 2021
Lophora Initiates Preclinical Development of LPH-5 for Treatment-Resistant Depression
- April 3, 2020